Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213257PMC
http://dx.doi.org/10.1097/CM9.0000000000001387DOI Listing

Publication Analysis

Top Keywords

comorbidity chronic
4
chronic fatigue
4
fatigue syndrome
4
syndrome postural
4
postural tachycardia
4
tachycardia syndrome
4
syndrome narcolepsy
4
narcolepsy 510-methylenetetrahydrofolate
4
510-methylenetetrahydrofolate reductase
4
reductase mthfr
4

Similar Publications

Background: There remains a paucity of data regarding the cardio-renal benefits of sodium-glucose co-transporter-2 inhibitors (SGLT2i) in patients with chronic kidney disease stage 5 (CKD V) based on major clinical trials.

Objective: This retrospective study aimed to identify potential cardiovascular and renal outcomes associated with SGLT2i use in CKD V patients.

Methods: We queried the TriNetX Global collaborative network from Jan 2014 - Aug 2023 for patients ≥18 years diagnosed with CKD V but not on dialysis.

View Article and Find Full Text PDF

Obstructive sleep apnea syndrome (OSAS) in women: A forgotten cardiovascular risk factor.

Maturitas

December 2024

Department of Translational and Precision Medicine, Sapienza-University of Rome, Viale del Policlinico 155, Rome 00161, Italy. Electronic address:

Sleep-disordered breathing is a highly prevalent disorder with negative impact on healthcare systems worldwide. This condition has detrimental effects on cardiovascular health and quality of life, and is frequently associated with a variety of comorbidities, including cardiovascular disease, heart failure, diabetes and atrial fibrillation. Nevertheless, it remains frequently undiagnosed and undertreated, especially in specific populations.

View Article and Find Full Text PDF

Purpose: Patients with vertebral osteomyelitis (VO) and comorbidities, notably chronic kidney disease (CKD), are at risk of early mortality. The aim of this study was to compare characteristics and outcomes of VO patients with an underlying malignancy (ONCO) to VO patients with CKD and VO patients without comorbidities (CONTROL).

Methods: We performed a retrospective analysis of data which was prospectively collected between 2008 and 2020.

View Article and Find Full Text PDF

Polypharmacy in older patients with asthma: hidden risks and opportunities for improvement.

Expert Rev Respir Med

December 2024

Division of Respiratory Medicine, PROMISE Department, "Paolo Giaccone" University Hospital, University of Palermo, Palermo, Italy.

Introduction: Polypharmacy can be considered the norm in elderly patients, because older individuals experience an increasing number of concomitant respiratory and non-respiratory diseases other than asthma, carrying the risk of drug-to-drug-interactions and drug-to-comorbidities interactions. In this context, asthma in older adults, conventionally aging >65 yrs of age, cannot be adequately managed without considering their individual characteristics, as these challenge the traditional therapeutic algorithms/management strategies commonly applied to younger populations.

Areas Covered: The current article aims at addressing pitfalls and advantages of current pharmacological strategies in older individuals with asthma.

View Article and Find Full Text PDF

Background: Chronic kidney disease (CKD) is frequently complicated by arrhythmias, plausibly leading to the increased risk of sudden cardiac death in this population. However, little is known about the association between CKD and third-degree atrioventricular block (3AVB) and need for permanent pacing.

Objectives: This study aimed to investigate the association between CKD and 3AVB.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!